Updated:
Biohaven Ltd.
Biohaven Ltd. was founded in 2013 by a team including CEO Vlad Coric, emerging from Yale's neuroscience ecosystem to address neurological diseases where...
Biohaven Ltd.
Biohaven Ltd. was founded in 2013 by a team including CEO Vlad Coric, emerging from Yale's neuroscience ecosystem to address neurological diseases where commercial investment had retreated. The firm's original wealth creation came not from venture-style early bets but from the clinical and regulatory execution of in-licensed compounds — most notably rimegepant, which became the oral CGRP antagonist Nurtec ODT. Biohaven's strategy centers on late-stage clinical assets in neurology and immunology, where it acquires or in-licenses compounds and manages them through Phase 2/3 trials to regulatory approval. The original portfolio spanned migraine, spinocerebellar ataxia, obsessive-compulsive disorder, and amyotrophic lateral sclerosis. Following the Pfizer transaction in October 2022, Biohaven Ltd. retains the non-migraine pipeline, including troriluzole for SCA and OCD, alongside an immunology platform and a molecular degraders unit. The firm's capital efficiency stems from running a lean internal team while maintaining an outsourced commercial infrastructure — it previously relied on Pfizer's sales force for the Nurtec launch. As of mid-2024, the company operated as a publicly traded entity (NYSE: BHVN) with a market capitalization of approximately $3 billion to $4 billion, reflecting the pipeline's risk-adjusted value. The leadership team includes Coric as CEO and a board that historically featured former Pfizer executives following the carve-out. The firm has not disclosed an AUM figure, as it operates through public equity and corporate partnerships rather than traditional fund structures. The company's philanthropic and academic ties remain anchored to Yale and the broader Connecticut biotech corridor. Biohaven's structural differentiator is its model as a carve-out acquirer and development shop — it identifies assets that large pharma deprioritizes, licenses them, and runs the regulatory gauntlet with a team that has stayed together across transactions. The 2022 Pfizer deal separated the commercial-stage asset from the clinical pipeline without dismantling the operator group, an architecture more common in private equity spin-outs than in public biotech and one that allowed the original team to restart immediately with the rump portfolio.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New Haven
Corporate office
New Haven, CT, United States
Principals
Vlad Coric
Chief Executive Officer
Sector focus
Frequently asked questions
How did Biohaven separate from the Pfizer transaction while keeping the same team in place?
In October 2022, Pfizer acquired Biohaven Pharmaceutical Holding Company Ltd., including the migraine franchise centered on Nurtec ODT, for approximately $11.6 billion. The original Biohaven had already spun out its non-CGRP pipeline into Biohaven Ltd. in May 2022, distributing shares of the new entity to existing shareholders. The management team, including CEO Vlad Coric, moved to Biohaven Ltd., which retained the clinical-stage neurology and immunology assets. (per the firm's May 2022 SEC filings)
What is Biohaven's lead clinical program following the Pfizer sale?
The lead asset is troriluzole, a glutamate modulator, in development for spinocerebellar ataxia (SCA) and obsessive-compulsive disorder (OCD). The company has reported positive Phase 3 data in SCA, showing a slowing of disease progression in a three-year study, and aims to file a New Drug Application with the FDA. (per the firm's official communications)
Does Biohaven operate internal drug discovery or only in-license assets?
Biohaven primarily relies on in-licensing and acquiring assets that reach Phase 2 or Phase 3, rather than conducting early-stage target discovery. The company in-licensed its original migraine compound rimegepant from Bristol-Myers Squibb. Its molecular degraders platform represents a partial exception, with some internal early-stage chemistry capabilities built through acquisitions and academic partnerships. (public record)
How does the company fund its operations without recurring product revenue?
Following the Pfizer transaction, Biohaven retained approximately $250 million in cash and has since raised additional capital through public equity offerings and structured partnerships. The company does not report a traditional AUM but operates as a publicly traded development-stage biotech with access to equity capital markets. Its lean structure — with no internal commercial sales force for the current pipeline — limits burn rate relative to peers. (per SEC filings, 2023-2024)
Which disease areas outside neurology does Biohaven target?
Beyond neurology, Biohaven has built an immunology division and a molecular degrader platform. The immunology programs, including early-stage assets acquired from various licensors, target inflammatory diseases. The molecular degraders unit, established partly through a 2021 acquisition of Kleo Pharmaceuticals, focuses on degrading extracellular disease-causing proteins — a complement to intracellular degradation approaches pursued by others. (per the firm's corporate presentations)
Who are Biohaven's key scientific collaborators?
Biohaven has historically maintained close ties to Yale University's neuroscience and drug discovery programs, with several founders and advisors holding Yale faculty appointments. The company also collaborates with Connecticut-based research organizations and has partnerships with larger pharmaceutical companies for specific licensing agreements, though post-2022 it has not disclosed a major ongoing pharma alliance. (public record)
How does Biohaven's governance reflect its spin-out structure?
The corporate governance shows continuity from the original Biohaven entity, with CEO Vlad Coric and several board members remaining across the restructuring. The board includes directors with large-pharma experience, including a former Pfizer executive, reflecting the ongoing relationship established during the 2022 acquisition of the commercial franchise. (per the firm's proxy statements)
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: